1. Home
  2. PFS vs MRUS Comparison

PFS vs MRUS Comparison

Compare PFS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFS
  • MRUS
  • Stock Information
  • Founded
  • PFS 1839
  • MRUS 2003
  • Country
  • PFS United States
  • MRUS Netherlands
  • Employees
  • PFS N/A
  • MRUS N/A
  • Industry
  • PFS Savings Institutions
  • MRUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PFS Finance
  • MRUS Health Care
  • Exchange
  • PFS Nasdaq
  • MRUS Nasdaq
  • Market Cap
  • PFS 2.5B
  • MRUS 2.9B
  • IPO Year
  • PFS N/A
  • MRUS 2016
  • Fundamental
  • Price
  • PFS $19.43
  • MRUS $39.74
  • Analyst Decision
  • PFS Strong Buy
  • MRUS Strong Buy
  • Analyst Count
  • PFS 5
  • MRUS 12
  • Target Price
  • PFS $22.60
  • MRUS $87.92
  • AVG Volume (30 Days)
  • PFS 522.3K
  • MRUS 658.9K
  • Earning Date
  • PFS 01-28-2025
  • MRUS 02-26-2025
  • Dividend Yield
  • PFS 4.92%
  • MRUS N/A
  • EPS Growth
  • PFS N/A
  • MRUS N/A
  • EPS
  • PFS 0.98
  • MRUS N/A
  • Revenue
  • PFS $526,013,000.00
  • MRUS $35,932,000.00
  • Revenue This Year
  • PFS N/A
  • MRUS N/A
  • Revenue Next Year
  • PFS $27.38
  • MRUS $57.49
  • P/E Ratio
  • PFS $19.93
  • MRUS N/A
  • Revenue Growth
  • PFS 13.26
  • MRUS N/A
  • 52 Week Low
  • PFS $13.07
  • MRUS $33.60
  • 52 Week High
  • PFS $22.24
  • MRUS $61.61
  • Technical
  • Relative Strength Index (RSI)
  • PFS 52.34
  • MRUS 39.51
  • Support Level
  • PFS $19.07
  • MRUS $38.52
  • Resistance Level
  • PFS $19.82
  • MRUS $47.75
  • Average True Range (ATR)
  • PFS 0.50
  • MRUS 2.02
  • MACD
  • PFS 0.14
  • MRUS -0.14
  • Stochastic Oscillator
  • PFS 81.07
  • MRUS 19.74

About PFS Provident Financial Services Inc

Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Share on Social Networks: